Patel Dinesh V PH D's Form 4 filing
Protagonist Therapeutics, Inc (PTGX) · filed Aug 12, 2026
- Accession no.
- 0001104659-26-095111
- Filed
- Aug 12, 2026, 6:43 PM ET
- Trade date
- Aug 10-11, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $14.9M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Patel Dinesh V PH DCIK 0001120477 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | Common Stock | MOption exerciseAcquired | +65,761 | $21.58 | +$1,419,122.38 | 589,239 | Direct | |
| Aug 10, 2026 | Common Stock | SSaleDisposed | −65,761 | $149.11F2 | −$9,805,622.71 | 523,478 | Direct | |
| Aug 11, 2026 | Common Stock | MOption exerciseAcquired | +34,239 | $21.58 | +$738,877.62 | 557,717 | Direct | |
| Aug 11, 2026 | Common Stock | SSaleDisposed | −34,239 | $148.52F3 | −$5,085,176.28 | 523,478 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | Common Stock | MOption exerciseDisposed | −65,761 | $0.00 | $0 | 159,239 | Direct | |
| Aug 11, 2026 | Common Stock | MOption exerciseDisposed | −34,239 | $0.00 | $0 | 125,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $147.41 to $151.29. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $147.64 to $151.30. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.